EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Ralf Stemkens iD, Veronique de Jager, Rodney Dawson, Andreas H Diacon, Kim Narunsky, Sherman D Padayachee, Martin J Boeree, Stijn W van Beek, Angela Colbers, Marieke J H Coenen, Elin M Svensson, Uwe Fuhr und 4 weitere

Antimicrobial Agents and Chemotherapy · 18.10.2023 · 67 (10)

DOI: 10.1128/aac.00683-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.10.2023. Verfasst von Ralf Stemkens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center , Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This publication was produced by PanACEA, which is part of the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) programme, supported by….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulating evidence supports the use of higher doses of rifampicin for tuberculosis (TB) treatment. Rifampicin is a potent inducer of metabolic enzymes and drug transporters, resulting in clinically relevant drug interactions. To assess the drug interaction potential of higher doses of rifampicin, we compared the effect of high-dose rifampicin (40 mg/kg daily, RIF40) and standard-dose rifampicin (10 mg/kg daily, RIF10) on the activities of major cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp). In this open-label, single-arm, two-period, fixed-order phenotyping cocktail study, adult participants with pulmonary TB received RIF10 (days 1–15), followed by RIF40 (days 16–30). A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A), and digoxin (P-gp). Intensive pharmacokinetic blood sampling was performed over 24 hours after probe drug intake. In all, 25 participants completed the study. Geometric mean ratios (90% confidence interval) of the total exposure (area under the concentration versus time curve, RIF40 versus RIF10) for each of the probe drugs were as follows: caffeine, 105% (96%–115%); tolbutamide, 80% (74%–86%); omeprazole, 55% (47%–65%); dextromethorphan, 77% (68%–86%); midazolam, 62% (49%–78%), and 117% (105%–130%) for digoxin. In summary, high-dose rifampicin resulted in no additional effect on CYP1A2, mild additional induction of CYP2C9, CYP2C19, CYP2D6, and CYP3A, and marginal inhibition of P-gp. Existing recommendations on managing drug interactions with rifampicin can remain unchanged for the majority of co-administered drugs when using high-dose rifampicin. Clinical Trials registration number NCT04525235 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP1A2Tuberculosis, PulmonaryAdultHumansMidazolamCytochrome P-450 CYP2D6CaffeineRifampinCytochrome P-450 CYP2C19Cytochrome P-450 CYP3ADextromethorphanTolbutamideCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemOmeprazoleDrug InteractionsDigoxin

Stichwörter der Autor:innen

drug interactionshigh-dose rifampicinmetabolic phenotypingtuberculosis

Substanzen

Cytochrome P-450 CYP1A2MidazolamCytochrome P-450 CYP2D6CaffeineRifampinCytochrome P-450 CYP2C19Cytochrome P-450 CYP3ADextromethorphanTolbutamideCytochrome P-450 CYP2C9

Autor:innen und Institutionen

  • Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center , Nijmegen, The Netherlands.
  • TASK , Cape Town, South Africa.
  • Division of Pulmonology and Department of Medicine, University of Cape Town and University of Cape Town Lung Institute , Cape Town, South Africa.
  • Department of Pulmonary Diseases, Research Institute for Medical Innovation, Radboud University Medical Center , Nijmegen, The Netherlands.
  • Department of Clinical Chemistry, Erasmus University Medical Center , Rotterdam, The Netherlands.
  • Department of Pharmacy, Uppsala University , Uppsala, Sweden.

ORCID-Profile: Ralf Stemkens

Förderung

  • This publication was produced by PanACEA, which is part of the European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) programme, supported by…

Zitieren

APA

Stemkens, R., Jager, V., Dawson, R., Diacon, A. H., Narunsky, K., Padayachee, S. D., Boeree, M. J., van Beek, S. W., Colbers, A., Coenen, M. J. H., Svensson, E. M., Fuhr, U., Phillips, P. P. J., Te Brake, L. H. M., Aarnoutse, R. E., & PanACEA consortium (2023). Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy, 67(10). https://doi.org/10.1128/aac.00683-23

Vancouver

Stemkens R, Jager V, Dawson R, Diacon AH, Narunsky K, Padayachee SD, et al. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy. 2023;67(10). doi:10.1128/aac.00683-23

BibTeX
@article{Stemkens2023,
  author = {Stemkens, Ralf and Jager, Veronique de and Dawson, Rodney and Diacon, Andreas H and Narunsky, Kim and Padayachee, Sherman D and Boeree, Martin J and van Beek, Stijn W and Colbers, Angela and Coenen, Marieke J H and Svensson, Elin M and Fuhr, Uwe and Phillips, Patrick P J and Te Brake, Lindsey H M and Aarnoutse, Rob E and PanACEA consortium, PanACEA consortium},
  title = {Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {10},
  doi = {10.1128/aac.00683-23}
}
Kostenlos starten →